Article successfully added.

CyFlow™ CD19 PerCP

CyFlow™ CD19 PerCP
Alternative Name: B4
Antibody: Yes
Antigen: CD19
Application: Flow cytometry
Clonality: monoclonal
Clone: LT19
Emission Maximum: 678 nm
Excitation Maximum: 482 to 490 nm
Field of Interest: Immunophenotyping
Format/Fluorochrome: PerCP
Isotype: IgG1
Laser: Blue , Green
Regulatory Status: RUO
Source Species: Mouse
Target Species: Human
Product number: CT134703

For Research Use Only

$265.00 USD*

Price excludes any applicable taxes plus shipping costs

Description Documentation TDS & SDS
Description
HLDA Workshop HCDM/HLDA 10 Quantity 100 tests Volume 1.0 mL Immunogen Daudi human... more
Close menu
CyFlow™ CD19 PerCP
HLDA WorkshopHCDM/HLDA 10
Quantity100 tests
Volume1.0 mL
ImmunogenDaudi human Burkitt lymphoma cell line
Background InformationCD19 is a transmembrane glycoprotein of Ig superfamily expressed by B cells from the time of heavy chain rearrangement until plasma cell differentiation. It forms a tetrameric complex with CD21 (complement receptor type 2), CD81 (TAPA-1) and Leu13. Together with BCR (B cell antigen receptor), this complex signals to decrease B cell treshold for activation by the antigen. Besides being signal-amplifying coreceptor for BCR, CD19 can also signal independently of BCR coligation and it turns out to be a central regulatory component upon which multiple signaling pathways converge. Mutation of the CD19 gene results in hypogammaglobulinemia, whereas CD19 overexpression causes B cell hyperactivity.
UsageThe reagent is designed for Flow Cytometry analysis of human blood cells. Recommended usage is 10·µl reagent·/ 100·µl of whole blood or 10^6 cells in a suspension. The content of a vial (1 ml) is sufficient for 100 tests.
Storage BufferThe reagent is provided in stabilizing phosphate buffered saline (PBS) solution, pH ≈7.4, containing 0.09% (w/v) sodium azide.
StorageAvoid prolonged exposure to light. Store in the dark at 2-8°C. Do not freeze.
StabilityDo not use after expiration date stamped on vial label.
Specific References

| Fujimoto M, Poe JC, Jansen PJ, Sato S, Tedder TF: CD19 amplifies B lymphocyte signal transduction by regulating Src‑family protein tyrosine kinase activation. J Immunol. 1999 Jun 15; 162(12):7088‑94. < PMID: 10358152 > | Inabe K, Kurosaki T: Tyrosine phosphorylation of B‑cell adaptor for phosphoinositide 3‑kinase is required for Akt activation in response to CD19 engagement. Blood. 2002 Jan 15; 99(2):584‑9. < PMID: 11781242 > | Elias F, Flo J, Lopez RA, Zorzopulos J, Montaner A, Rodriguez JM: Strong cytosine‑guanosine‑independent immunostimulation in humans and other primates by synthetic oligodeoxynucleotides with PyNTTTTGT motifs. J Immunol. 2003 Oct 1; 171(7):3697‑704. < PMID: 14500668 > | Lin CW, Liu TY, Chen SU, Wang KT, Medeiros LJ, Hsu SM: CD94 1A transcripts characterize lymphoblastic lymphoma/leukemia of immature natural killer cell origin with distinct clinical features. Blood. 2005 Nov 15; 106(10):3567‑74. < PMID: 16046525 > | van Zelm MC, Reisli I, van der Burg M, Castaño D, van Noesel CJ, van Tol MJ, Woellner C, Grimbacher B, Patiño PJ, van Dongen JJ, Franco JL: An antibody‑deficiency syndrome due to mutations in the CD19 gene. N Engl J Med. 2006 May 4; 354(18):1901‑12. < PMID: 16672701 > | Shi X, Xie C, Chang S, Zhou XJ, Tedder T, Mohan C: CD19 hyperexpression augments Sle1‑induced humoral autoimmunity but not clinical nephritis. Arthritis Rheum. 2007 Sep; 56(9):3057‑69. < PMID: 17763445 > | Stehlíková O, Chovancová J, Tichý B, Krejčí M, Brychtová Y, Panovská A, Francová Skuhrová H, Burčková K, Borský M, Loja T, Mayer J, Pospíšilová S, Doubek M: Detecting minimal residual disease in patients with chronic lymphocytic leukemia using 8‑color flow cytometry protocol in routine hematological practice. Int J Lab Hematol. 2014 Apr; 36(2):165‑71. < PMID: 24028768 >

TDS & SDS
Close menu

Technical Data Sheet

Safety Data Sheet